Abstract:Abstract Background Ubiquitin‐conjugating enzyme E2S (UBE2S), an E2 enzyme, is associated with the development of various tumors and exerts oncogenic activities. UBE2S is overexpressed in tumors, including hepatocellular carcinoma (HCC). However, the key molecular mechanisms of UBE2S in HCC still need additional research. The aim of this study was to explore the role of UBE2S in HCC. Methods The expression levels of UBE2S in HCC tissues and cells were detected by western blot analysis, quantitative real‐time polymerase chain reaction analysis (qRT–PCR), and immunohistochemistry (IHC). A 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyl‐2H‐tetrazolium bromide (MTT) assay, wound healing assay, colony formation assay transwell assay, and animal models were used to detect the proliferation and migration ability of HCC cells. Western blot analysis, qRT–PCR, immunofluorescence, small‐interfering RNA (siRNA), and plasmid transfection and coimmunoprecipitation (Co‐IP) assays were performed to detect the interaction among UBE2S, von Hippel–Lindau (VHL), hypoxia‐inducible factor 1‐alpha (HIF‐1α), Janus kinase‐2 (JAK2), and signal transducer and activator of transcription 3 (STAT3). Results In this study, we found that high UBE2S expression was associated with poor prognosis in HCC patients. In addition, UBE2S expression was upregulated in HCC tissues and cell lines. Knockdown of UBE2S inhibited the proliferation and migration of HCC cells in vitro and in vivo by directly interacting with VHL to downregulate the HIF‐1α and JAK2/STAT3 signaling pathways. Accordingly, overexpression of UBE2S significantly enhanced the proliferation and migration of HCC cells in vitro via VHL to upregulate HIF‐1α and JAK2/STAT3 signaling pathways. Furthermore, we found that downregulation of UBE2S expression enhanced the sensitivity of HCC cells to sorafenib in vivo and in vitro. Conclusion UBE2S enhances malignant properties via the VHL/HIF‐1α and VHL/JAK2/STAT3 signaling pathways and reduces sensitivity to sorafenib in HCC. The findings of this study may open a new approach for HCC diagnosis and provide a potential option for the treatment of HCC.

UBAP2 Negatively Regulates the Invasion of Hepatocellular Carcinoma Cell by Ubiquitinating and Degradating Annexin A2

Downregulation of UBAP2L Inhibits the Epithelial-Mesenchymal Transition Via SNAIL1 Regulation in Hepatocellular Carcinoma Cells

ABHD17C Represses Apoptosis and Pyroptosis in Hepatocellular Carcinoma Cells

Comprehensive Analysis of Ubiquitin‐specific Protease 1 Reveals Its Importance in Hepatocellular Carcinoma

UBA2 SUMOylates NQO1 and promotes the proliferation of hepatocellular carcinoma by modulating the MAPK pathway

Dysregulation and oncogenic activities of ubiquitin specific peptidase 2a in the pathogenesis of hepatocellular carcinoma

Identification of the Potential Therapeutic Target Gene UBE2C in Human Hepatocellular Carcinoma: an Investigation Based on GEO and TCGA Databases

[Effects of Annexin A2 gene transcription down-regulation on human hepatoma cell biological behaviour]

Polycomb Protein Ezh2 Activates Wnt/Beta-Catenin Signaling To Promote Hepatocellular Carcinoma Development

BAIAP2L2 promotes the malignancy of hepatocellular carcinoma via GABPB1-mediated reactive oxygen species imbalance

Inhibition of UBA52 induces autophagy via EMC6 to suppress hepatocellular carcinoma tumorigenesis and progression

The activation of the Notch signaling pathway by UBE2C promotes the proliferation and metastasis of hepatocellular carcinoma

OTUB2 Promotes Proliferation and Migration of Hepatocellular Carcinoma Cells by PJA1 Deubiquitylation

UBE2M Promotes Cell Proliferation Via the Β-Catenin/cyclin D1 Signaling in Hepatocellular Carcinoma

UBE2S Promotes Malignant Properties Via VHL/HIF‐1α and VHL/JAK2/STAT3 Signaling Pathways and Decreases Sensitivity to Sorafenib in Hepatocellular Carcinoma

CircRNA UBAP2 Serves As a Sponge of Mir-1294 to Increase Tumorigenesis in Hepatocellular Carcinoma Through Regulating C-Myc Expression.

mRNA sequencing and CyTOF analysis revealed ASPP2 altered the response patterns of hepatocellular carcinoma HepG2 cells to usnic acid

Low Expression of Phosphodiesterase 2 (PDE2A) Promotes the Progression by Regulating Mitochondrial Morphology and ATP Content and Predicts Poor Prognosis in Hepatocellular Carcinoma

Ube2j2 Promotes Hepatocellular Carcinoma Cell Epithelial-Mesenchymal Transition And Invasion In Vitro

Annexin A2 Enhances the Progression of Colorectal Cancer and Hepatocarcinoma via Cytoskeleton Structural Rearrangements

ANXA2 enhances the progression of hepatocellular carcinoma via remodeling the cell motility associated structures